Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. Pathological Evaluation
2.3. Statistical Analysis
3. Results
3.1. Patient Selection and Baseline Clinicopathological Information
3.2. Alteration of ER, PR, and Ki-67 Expression after Neoadjuvant Therapy
3.3. PR Loss Was Associated with Baseline PR Score but Not with Ki-67 Alteration
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Johnston, S.J.; Cheung, K.L. Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation. Oncol. Ther. 2018, 6, 141–156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marti, C.; Sanchez-Mendez, J.I. The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment. Cancers 2021, 13, 2538. [Google Scholar] [CrossRef] [PubMed]
- Ellis, M.J.; Suman, V.J.; Hoog, J.; Lin, L.; Snider, J.; Prat, A.; Parker, J.S.; Luo, J.; DeSchryver, K.; Allred, D.C.; et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. J. Clin. Oncol. 2011, 29, 2342–2349. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, J.; Lu, C.Y.; Chen, H.M.; Wu, S.Y. Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast with High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity. JAMA Netw. Open 2021, 4, e211785. [Google Scholar] [CrossRef] [PubMed]
- Sugiu, K.; Iwamoto, T.; Kelly, C.M.; Watanabe, N.; Motoki, T.; Ito, M.; Ohtani, S.; Higaki, K.; Imada, T.; Yuasa, T.; et al. Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer: NACED-Randomized Multicenter Phase II Trial. Acta Med. Okayama 2015, 69, 291–299. [Google Scholar] [CrossRef] [PubMed]
- Yu, K.D.; Wu, S.Y.; Liu, G.Y.; Wu, J.; Di, G.H.; Hu, Z.; Hou, Y.F.; Chen, C.M.; Fan, L.; Tang, L.C.; et al. Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial. Cancer 2019, 125, 2185–2193. [Google Scholar] [CrossRef]
- Allison, K.H.; Hammond, M.E.H.; Dowsett, M.; McKernin, S.E.; Carey, L.A.; Fitzgibbons, P.L.; Hayes, D.F.; Lakhani, S.R.; Chavez-MacGregor, M.; Perlmutter, J.; et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J. Clin. Oncol. 2020, 38, 1346–1366. [Google Scholar] [CrossRef] [PubMed]
- Peng, J.H.; Zhang, X.; Song, J.L.; Ran, L.; Luo, R.; Li, H.Y.; Wang, Y.H. Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma. Medicine 2019, 98, e13554. [Google Scholar] [CrossRef] [PubMed]
- Rey-Vargas, L.; Mejia-Henao, J.C.; Sanabria-Salas, M.C.; Serrano-Gomez, S.J. Effect of neoadjuvant therapy on breast cancer biomarker profile. BMC Cancer 2020, 20, 675. [Google Scholar] [CrossRef] [PubMed]
- Smith, I.E.; Dowsett, M.; Ebbs, S.R.; Dixon, J.M.; Skene, A.; Blohmer, J.U.; Ashley, S.E.; Francis, S.; Boeddinghaus, I.; Walsh, G.; et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 2005, 23, 5108–5116. [Google Scholar] [CrossRef]
- Eiermann, W.; Paepke, S.; Appfelstaedt, J.; Llombart-Cussac, A.; Eremin, J.; Vinholes, J.; Mauriac, L.; Ellis, M.; Lassus, M.; Chaudri-Ross, H.A.; et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann. Oncol. 2001, 12, 1527–1532. [Google Scholar] [CrossRef] [PubMed]
- Niikura, N.; Tomotaki, A.; Miyata, H.; Iwamoto, T.; Kawai, M.; Anan, K.; Hayashi, N.; Aogi, K.; Ishida, T.; Masuoka, H.; et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. Ann. Oncol. 2016, 27, 480–487. [Google Scholar] [CrossRef] [PubMed]
- Ellis, M.J.; Tao, Y.; Luo, J.; A’Hern, R.; Evans, D.B.; Bhatnagar, A.S.; Chaudri Ross, H.A.; von Kameke, A.; Miller, W.R.; Smith, I.; et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J. Natl. Cancer Inst. 2008, 100, 1380–1388. [Google Scholar] [CrossRef]
- Wang, X.; Fan, Z.; Wang, X.; He, Y.; Liu, Y.; Wang, X.; Zhang, B.; Jiang, Z.; Wang, T.; Yu, Z.; et al. Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: Results of a prospective multi-center study. Breast Cancer Res. Treat. 2022, 195, 301–310. [Google Scholar] [CrossRef] [PubMed]
- Hu, T.; Liu, Y.; Wu, J.; Hu, X.L.; Zhao, G.; Liang, B.; Wang, S.; Long, M. Triple-Negative Apocrine Breast Carcinoma Has Better Prognosis despite Poor Response to Neoadjuvant Chemotherapy. J. Clin. Med. 2022, 11, 1607. [Google Scholar] [CrossRef]
- Allred, D.C.; Harvey, J.M.; Berardo, M.; Clark, G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998, 11, 155–168. [Google Scholar]
- Harvey, J.M.; Clark, G.M.; Osborne, C.K.; Allred, D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999, 17, 1474–1481. [Google Scholar] [CrossRef]
- Fontein, D.B.; Charehbili, A.; Nortier, J.W.; Meershoek-Klein Kranenbarg, E.; Kroep, J.R.; Putter, H.; van Riet, Y.; Nieuwenhuijzen, G.A.; de Valk, B.; Terwogt, J.M.; et al. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients—A phase II trial. Eur. J. Cancer 2014, 50, 2190–2200. [Google Scholar] [CrossRef]
- Dixon, J.M.; Renshaw, L.; Macaskill, E.J.; Young, O.; Murray, J.; Cameron, D.; Kerr, G.R.; Evans, D.B.; Miller, W.R. Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res. Treat. 2009, 113, 145–151. [Google Scholar] [CrossRef]
- Ahn, S.; Kim, H.J.; Kim, M.; Chung, Y.R.; Kang, E.; Kim, E.K.; Kim, S.H.; Kim, Y.J.; Kim, J.H.; Kim, I.A.; et al. Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer. Cancer Res. Treat. 2018, 50, 1418–1432. [Google Scholar] [CrossRef] [Green Version]
- Kurozumi, S.; Matsumoto, H.; Inoue, K.; Tozuka, K.; Hayashi, Y.; Kurosumi, M.; Oyama, T.; Fujii, T.; Horiguchi, J.; Kuwano, H. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer. PLoS ONE 2018, 13, e0201846. [Google Scholar] [CrossRef] [PubMed]
- Hu, T.; Chen, Y.; Liu, Y.; Zhang, D.; Pan, J.; Long, M. Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores. BMC Med. Res. Methodol. 2021, 21, 108. [Google Scholar] [CrossRef]
- Yao, N.; Song, Z.; Wang, X.; Yang, S.; Song, H. Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients. J. Breast Cancer 2017, 20, 160–169. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Yang, D.; Yin, X.; Zhang, X.; Huang, J.; Wu, Y.; Wang, M.; Yi, Z.; Li, H.; Li, H.; et al. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients with Single Hormone Receptor-Positive Breast Cancer. JAMA Netw. Open 2020, 3, e1918160. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schrijver, W.; Suijkerbuijk, K.P.M.; van Gils, C.H.; van der Wall, E.; Moelans, C.B.; van Diest, P.J. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. J. Natl. Cancer Inst. 2018, 110, 568–580. [Google Scholar] [CrossRef] [Green Version]
- Muti, P. Is progesterone a neutral or protective factor for breast cancer? Nat. Rev. Cancer 2014, 14, 146. [Google Scholar] [CrossRef]
- Brisken, C. Progesterone signalling in breast cancer: A neglected hormone coming into the limelight. Nat. Rev. Cancer 2013, 13, 385–396. [Google Scholar] [CrossRef]
- Tanos, T.; Sflomos, G.; Echeverria, P.C.; Ayyanan, A.; Gutierrez, M.; Delaloye, J.F.; Raffoul, W.; Fiche, M.; Dougall, W.; Schneider, P.; et al. Progesterone/RANKL is a major regulatory axis in the human breast. Sci. Transl. Med. 2013, 5, 182ra155. [Google Scholar] [CrossRef] [Green Version]
- Alkhalaf, M.; El-Mowafy, A.; Karam, S. Growth inhibition of MCF-7 human breast cancer cells by progesterone is associated with cell differentiation and phosphorylation of Akt protein. Eur. J. Cancer Prev. 2002, 11, 481–488. [Google Scholar] [CrossRef]
- Lin, V.C.; Eng, A.S.; Hen, N.E.; Ng, E.H.; Chowdhury, S.H. Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231. Clin. Cancer Res. 2001, 7, 2880–2886. [Google Scholar]
- Schernhammer, E.S.; Sperati, F.; Razavi, P.; Agnoli, C.; Sieri, S.; Berrino, F.; Krogh, V.; Abbagnato, C.; Grioni, S.; Blandino, G.; et al. Endogenous sex steroids in premenopausal women and risk of breast cancer: The ORDET cohort. Breast Cancer Res. 2013, 15, R46. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Inda, M.A.; Blok, E.J.; Kuppen, P.J.K.; Charehbili, A.; den Biezen-Timmermans, E.C.; van Brussel, A.; Fruytier, S.E.; Meershoek-Klein Kranenbarg, E.; Kloet, S.; van der Burg, B.; et al. Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer. Mol. Cancer Ther. 2020, 19, 680–689. [Google Scholar] [CrossRef] [PubMed]
- Chic, N.; Schettini, F.; Braso-Maristany, F.; Sanfeliu, E.; Adamo, B.; Vidal, M.; Martinez, D.; Galvan, P.; Gonzalez-Farre, B.; Cortes, J.; et al. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. EBioMedicine 2021, 69, 103451. [Google Scholar] [CrossRef] [PubMed]
- Brechbuhl, H.M.; Xie, M.; Kopin, E.G.; Han, A.L.; Vinod-Paul, K.; Hagen, J.; Edgerton, S.; Owens, P.; Sams, S.; Elias, A.; et al. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Mol. Carcinog. 2021, 61, 359–371. [Google Scholar] [CrossRef]
Cohort-C | Cohort-E | Cohort-EC | p-Value | |
---|---|---|---|---|
Total patients | 633 | 314 | 247 | |
Age (years) 1 | 48.9 (9.9) | 57.8 (10.5) | 51.3 (10.3) | <0.001 |
Histology 2 | 0.492 | |||
IDC-NST | 587 (92.7) | 288 (91.7) | 233 (94.3) | |
Special subtype | 46 (7.3) | 26 (8.3) | 14 (5.7) | |
Histological grade 2 | <0.001 | |||
I | 88 (13.9) | 62 (19.7) | 35 (14.2) | |
II | 472 (74.6) | 244 (77.7) | 192 (77.7) | |
III | 73 (11.5) | 8 (2.5) | 20 (8.1) | |
Surgery type 2 | <0.001 | |||
BCS | 242 (38.2) | 197 (62.7) | 138 (55.9) | |
Mastectomy | 391 (61.8) | 117 (37.3) | 109 (44.1) | |
ER Allred score 2 | <0.001 | |||
3/4/5 | 61 (9.6) | 2 (0.6) | 17 (6.9) | |
6/7/8 | 572 (90.4) | 312 (99.4) | 230 (93.1) | |
PR Allred score 2 | 0.001 | |||
0/2 | 63 (10.0) | 13 (4.1) | 15 (6.1) | |
3/4/5 | 140 (22.1) | 51 (16.2) | 49 (19.8) | |
6/7/8 | 430 (67.9) | 250 (79.6) | 183 (74.1) | |
Ki-67 (%) 1 | 34.3 (22.5) | 21.9 (16.9) | 33.7 (21.8) | <0.001 |
NET duration (months) 1 | N/A | 9.9 (8.3) | 8.5 (7.5) | 0.043 |
Use of aromatase inhibitor 2 | <0.001 | |||
No | 633 (100.0) | 29 (9.2) | 40 (16.2) | |
Yes | 0 (0.0) | 285 (90.8) | 207 (83.8) |
Cohort-C | Cohort-E | Cohort-EC | |||||||
---|---|---|---|---|---|---|---|---|---|
Before | After | Before | After | Before | After | ||||
ER Allred score 1 | p < 0.001 | p < 0.001 | p < 0.001 | ||||||
0/2 | 13 (5.3) | 1 (0.5) | 8 (5.4) | ||||||
3/4/5 | 17 (7.0) | 14 (5.8) | 2 (1.1) | 6 (3.2) | 7 (4.7) | 6 (4.0) | |||
6/7/8 | 226 (93.0) | 216 (88.9) | 185 (98.9) | 180 (96.3) | 142 (95.3) | 135 (90.6) | |||
PR Allred score | p < 0.001 | p < 0.001 | p < 0.001 | ||||||
0/2 | 20 (8.2) | 47 (19.3) | 9 (4.8) | 60 (32.1) | 7 (4.7) | 38 (25.5) | |||
3/4/5 | 64 (26.3) | 81 (33.3) | 35 (18.7) | 72 (38.5) | 26 (17.4) | 49 (32.9) | |||
6/7/8 | 159 (65.4) | 115 (47.3) | 143 (76.5) | 55 (29.4) | 116 (77.9) | 62 (41.6) | |||
Ki-67(%), mean (SD) | 32.4 (21.0) | 14.0 (16.3) | p < 0.001 | 21.5 (17.7) | 10.8 (14.7) | p < 0.001 | 31.3 (21.1) | 13.7 (17.9) | p < 0.001 |
HER2 | p < 0.001 | p < 0.001 | p < 0.001 | ||||||
0 | 48 (19.8) | 74 (30.5) | 29 (15.5) | 65 (34.8) | 32 (21.5) | 51 (34.2) | |||
1 | 107 (44.0) | 80 (32.9) | 95 (50.8) | 88 (47.1) | 66 (44.3) | 59 (39.6) | |||
2 | 88 (36.2) | 87 (35.8) | 63 (33.7) | 31 (16.6) | 51 (34.2) | 37 (24.8) | |||
3 | 1 (0.4) | 1 (0.7) | |||||||
Unknown | 1 (0.4) | 3 (1.6) | 1 (0.7) |
Age ≤ 60 Years (n = 106) | Age > 60 Years (n = 81) | p-Value | NET Length ≤6 Months (n = 92) | NET Length >6 Months (n = 95) | p-Value | |
---|---|---|---|---|---|---|
ER | 0.68 | 0.2 | ||||
Decrease (%) | 40.6 | 37.0 | 30.9 | 45.3 | ||
Even (%) | 53.8 | 59.3 | 58.8 | 50.5 | ||
Decrease (%) | 5.7 | 3.7 | 5.2 | 4.2 | ||
PR | 0.42 | 0.53 | ||||
Decrease (%) | 80.2 | 84.0 | 79.4 | 80.0 | ||
Even (%) | 17.0 | 11.1 | 11.3 | 16.8 | ||
Decrease (%) | 2.8 | 4.9 | 4.1 | 3.2 | ||
Ki-67 | 0.87 | 0.37 | ||||
Decrease (%) | 80.4 | 78.8 | 83.1 | 76.3 | ||
Even (%) | 6.9 | 8.8 | 4.5 | 10.8 | ||
Decrease (%) | 12.7 | 12.5 | 12.4 | 12.9 |
PR-Loss | PR-Preserved | p-Value | |
---|---|---|---|
Total patients | 53 | 125 | |
Age (years, mean (SD)) 1 | 58.6 (9.0) | 57.4 (11.5) | 0.503 |
Histology 2 | 0.028 | ||
IDC-NST | 46 (86.8) | 121 (96.8) | |
Special subtype | 7 (13.2) | 4 (3.2) | |
Histological grade 2 | 0.604 | ||
I | 10 (18.9) | 28 (22.4) | |
II | 41 (77.4) | 95 (76.0) | |
III | 2 (3.8) | 2 (1.6) | |
Surgery type 2 | 0.285 | ||
BCS | 37 (69.8) | 75 (60.0) | |
Mastectomy | 16 (30.2) | 50 (40.0) | |
ER Allred score (pre) 2 | 1.000 | ||
3/4/5 | 1 (1.9) | 1 (0.8) | |
6/7/8 | 52 (98.1) | 124 (99.2) | |
ER Allred score (post) 2 | 0.274 | ||
0/2 | 1 (1.9) | ||
3/4/5 | 1 (1.9) | 4 (3.2) | |
6/7/8 | 51 (96.2) | 121 (96.8) | |
PR Allred score (pre) 2 | 0.001 | ||
3/4/5 | 19 (35.8) | 16 (12.8) | |
6/7/8 | 34 (64.2) | 109 (87.2) | |
PR Allred score (post) 2 | < 0.001 | ||
0/2 | 53 (100.0) | ||
3/4/5 | 70 (56.0) | ||
6/7/8 | 55 (44.0) | ||
Ki-67 (%, pre) 1 | 22.9 (18.5) | 20.6 (17.4) | 0.428 |
Ki-67 (%, post) 1 | 8.4 (13.2) | 10.4 (12.8) | 0.370 |
EGFR (pre) 2 | 0.498 | ||
0 | 38 (71.7) | 80 (64.0) | |
1 | 3 (5.7) | 13 (10.4) | |
Unknown | 12 (22.6) | 32 (25.6) | |
EGFR (post) 2 | 0.236 | ||
0 | 41 (77.4) | 96 (76.8) | |
1 | 12 (22.6) | 23 (18.4) | |
Unknown | 6 (4.8) | ||
HER2 (pre) 2 | 0.439 | ||
0 | 7 (13.2) | 20 (16.0) | |
1 | 31 (58.5) | 60 (48.0) | |
2 | 15 (28.3) | 45 (36.0) | |
HER2 (post) 2 | 0.780 | ||
0 | 15 (28.3) | 45 (36.0) | |
1 | 27 (50.9) | 59 (47.2) | |
2 | 10 (18.9) | 19 (15.2) | |
Unknown | 1 (1.9) | 2 (1.6) | |
NET duration (months) 1 | 10.1 (9.2) | 9.1 (6.6) | 0.378 |
Use of aromatase inhibitor 2 | 0.377 | ||
No | 1 (1.9) | 8 (6.4) | |
Yes | 52 (98.1) | 117 (93.6) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Long, M.; You, C.; Song, Q.; Hu, L.X.J.; Guo, Z.; Yao, Q.; Hou, W.; Sun, W.; Liang, B.; Zhou, X.-H.; et al. Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer. Life 2023, 13, 74. https://doi.org/10.3390/life13010074
Long M, You C, Song Q, Hu LXJ, Guo Z, Yao Q, Hou W, Sun W, Liang B, Zhou X-H, et al. Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer. Life. 2023; 13(1):74. https://doi.org/10.3390/life13010074
Chicago/Turabian StyleLong, Mengping, Chong You, Qianqian Song, Lina X. J. Hu, Zhaorong Guo, Qian Yao, Wei Hou, Wei Sun, Baosheng Liang, Xiao-Hua Zhou, and et al. 2023. "Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer" Life 13, no. 1: 74. https://doi.org/10.3390/life13010074